Kyle Doherty
Articles
Venetoclax/Obinutuzumab Continues to Show Efficacy in Unfit Patients with CLL
June 30, 2022
Article
An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.
Patritumab Deruxtecan Produces Early Responses in Advanced NSCLC Regardless of Variant Genomic Alterations
June 17, 2022
Article
Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.
Revolutionizing Patient-Reported Outcomes in Oncology Care
May 29, 2022
Article
Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.
GnRH Agonists Demonstrate Utility in Preventing Premature Menopause in Women With Breast Cancer
May 23, 2022
Article
Current ASCO guidelines recommend that providers discuss the possibility of infertility with their patients as soon as possible before treatment begins.
Newly Approved Pacritinib Continues to Reduce Symptom Burden in Myelofibrosis With Moderate/Severe Thrombocytopenia
April 20, 2022
Article
Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.
Niraparib/Bevacizumab Combo Elicits Promising Responses in Advanced Ovarian Cancer, Regardless of Biomarker Status
March 31, 2022
Article
The PARP inhibitor, niraparib, in conjunction with the VEGF inhibitor, bevacizumab, resulted in encouraging responses from patients with advanced ovarian cancer.
Investigational CAR T-Cell Therapy, Obecabtagene Autoleucel, Is Poised to Fill Unmet Need in Relapsed/Refractory B-ALL
March 22, 2022
Article
Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Metastatic Urothelial Cancer Treatments Continue to Gravitate Towards Immunotherapy and Targeted Therapies
March 16, 2022
Article
A Yale Cancer Center expert offers a quick glance at the metastatic urothelial cancer treatment landscape.
Patients with LBCL Experience Improved Quality of Life Following Axi-Cel Treatment
December 17, 2021
Article
Axicabtagene ciloleucel improved the quality of life in patients with relapsed/refractory large B-cell lymphoma receiving the agent as a second-line therapy.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial Cancer
November 21, 2021
Article
A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.